26 recruiting, 23 not yet recruiting, 6 active not recruiting, 3 completed. 28 Phase 2, 17 Phase 1, 7 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow NSCLC (Advanced Non-small Cell Lung Cancer): new trials by email Literature Review of NSCLC (Advanced Non-small Cell Lung Cancer) trials Research Report on NSCLC (Advanced Non-small Cell Lung Cancer)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-10-22 |
| A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer JYP0322 Tablets, Crizotinib Capsules - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 216 | 2026-10-30 | 2026-09-22 |
| Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy - EGFR-mutant Non-small Cell Lung Cancer, SBRT | Phase 2 | Not yet recruiting | Fudan University | 374 | 2026-10-01 | 2026-09-16 |
| Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Multitude Therapeutics Inc. | 512 | 2026-08-28 | 2026-08-10 |
| Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Gemcitabine + Ivonescimab - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Swiss Cancer Institute | 47 | 2026-08-21 | 2026-08-26 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. ALK201 for injection, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 156 | 2026-08-20 | 2026-08-03 |
| Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy - NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | BOE Technology Group Co., Ltd. | 42 | 2026-08-01 | 2026-08-26 |
| Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer Pucotenlimab, Becotatug vedotin, Radiotherapy - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 39 | 2026-07-15 | 2026-06-04 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 252 | 2026-06-30 | 2026-05-22 |
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
| Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC radiotherapy, PD -1/PD-L1 monoclonal antibody - NSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 38 | 2026-06-01 | 2026-01-20 |
| Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin - NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-29 | 2026-06-22 | |
| GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer ArmA:GFH375, Arm B:GFH375, Arm C:GFH375 - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 90 | 2026-05-20 | 2026-04-28 |
| Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases sac-TMT plus EGFR-TKI - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 45 | 2026-05-01 | 2026-01-15 |
| Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure Tislelizumab, Docetaxel, Microwave ablation - NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2026-05-01 | 2026-04-14 |
| A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） SCTB41, docetaxel - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 90 | 2026-05-01 | 2026-05-27 |
| Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 204 | 2026-05-01 | 2026-05-01 |
Showing 20 of 60. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (60) · Colorectal Neoplasms (6) · Lung Neoplasms (5) · Mesothelioma (3) · Neoplasm Metastasis (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Endometrial Neoplasms (2) · Melanoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Venous Thromboembolism (2) · Ataxia Telangiectasia (1) · Breast Neoplasms (1)
Bronchial Neoplasms (60) · Carcinoma, Bronchogenic (60) · Lung Diseases (60) · Neoplasms by Site (60) · Respiratory Tract Diseases (60) · Respiratory Tract Neoplasms (60) · Thoracic Neoplasms (60) · Neoplasms (59) · Lung Neoplasms (55) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Neoplasms by Histologic Type (9) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Neoplasms, Glandular and Epithelial (8)
Carboplatin (8) · Pemetrexed (8) · Docetaxel (6) · Cisplatin (5) · pembrolizumab (4) · 130-nm albumin-bound paclitaxel (3) · Bevacizumab (3) · Gemcitabine (3) · Injections (3) · Paclitaxel (3) · osimertinib (3) · Cetuximab (2) · Radiotherapy (2) · aflutinib (2) · aumolertinib (2)
Fudan University (7) · Anhui Provincial Cancer Hospital (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Shanghai Allink Biotherapeutics Co., Ltd. (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · ALX Oncology Inc. (1) · Aktis Oncology, Inc. (1) · Allist Pharmaceuticals, Inc. (1) · Aromics Therapeutics (1) · BOE Technology Group Co., Ltd. (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · BlossomHill Therapeutics (1) · Daiichi Sankyo (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1)
China (28) · United States (10) · Belgium (5) · France (5) · Italy (5) · Spain (5) · Switzerland (4) · Australia (3) · Germany (3) · United Kingdom (3) · Hong Kong (2) · Israel (2) · Japan (2) · Singapore (2) · South Korea (2)
Yilong Wu (2) · Alessandra Curioni-Fontecedro, Prof (1) · Ari Raphael (1) · Caitlin Shonewolf, MD (1) · Dr. Christian Meisel, MD PhD (1) · Fuming Qiu, PhD (1) · Haibo Zhang, M.D. (1) · Hui Li, Doctor (1) · Jialei Wang, MD (1) · Jinming Yu, Dr (1) · Junqiang Fan, PhD (1) · Marcello Tiseo, MD, PhD (1) · Martin Wermke, Prof. Dr. (1)
PMID 29101058, PMID 29786478, PMID 31319971, PMID 32980443, PMID 33538338, PMID 35658002, PMID 35946540, PMID 36156007